{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T08:08:29Z","timestamp":1790842109072,"version":"4.1.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T00:00:00Z","timestamp":1754870400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T00:00:00Z","timestamp":1754870400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003790","name":"Hiroshima University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003790","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To determine prognostic parameters, we extensively examined whether physical, biochemical, and histological factors were associated with clinical outcomes in metastatic hormone sensitive prostate cancer (mHSPC) patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A total 822 mHSPC patients were retrospectively investigated and examined the associations between prognosis and clinicopathological parameters including BMI, initial PSA level, TNM classification, Hb, Alb, CRP, AST, ALT, LDH, ALP, Gleason grade group, and EOD score.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>According to the CHAARTED criteria, 338 (41.1%) and 484 (58.9%) patients were classified into low- and high-volume disease, respectively. In univariate and multivariate analyses, Gleason grade group, Alb, CRP, LDH, and ALP were determined as significant predictors for both PFS and OS. When mHSPC patients were classified into three group including favorable (none of risk factors), intermediate (one or two risk factors) and poor (more than three risk factors) according to these four parameters, the survival curves were significantly stratified according to the risk classification. When the risk classification was applied on the patients with low- or high-volume disease in CHAARTED criteria, worse prognosis was found in poor risk group patients with low-volume disease and favorable prognosis was found in favorable risk group patients with high-volume disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>These results suggested that Gleason grade, CRP, LDH, and ALP were the independent predictors for mHSPC patients regardless of metastatic burden.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00345-025-05862-4","type":"journal-article","created":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T12:54:30Z","timestamp":1754916870000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Risk classification by pathological and biochemical prognostic factors determined by extensive exploration for metastatic hormone sensitive prostate cancer"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3580-1401","authenticated-orcid":false,"given":"Keisuke","family":"Goto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2098-3916","authenticated-orcid":false,"given":"Kohei","family":"Kobatake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichiro","family":"Fukuoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshito","family":"Kagiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoya","family":"Hatayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumiaki","family":"Kirishima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuma","family":"Yukihiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshimasa","family":"Kurimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takumi","family":"Ikai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohei","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Shirane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Yasumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7014-6812","authenticated-orcid":false,"given":"Nobuyuki","family":"Hinata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,11]]},"reference":[{"issue":"1","key":"5862_CR1","first-page":"12","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A (2024) Cancer statistics, 2024. CA Cancer J Clin 74(1):12\u201349","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"5862_CR2","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1111\/iju.13091","volume":"23","author":"M Shiota","year":"2016","unstructured":"Shiota M, Eto M (2016) Current status of primary pharmacotherapy and future perspectives toward upfront therapy for metastatic hormone-sensitive prostate cancer. Int J Urol 23(5):360\u2013369","journal-title":"Int J Urol"},{"key":"5862_CR3","first-page":"100606","volume":"32","author":"L Blas","year":"2022","unstructured":"Blas L, Shiota M, Eto M (2022) Current status and future perspective on the management of metastatic castration-sensitive prostate cancer. Cancer Treat Res Commun 32:100606","journal-title":"Cancer Treat Res Commun"},{"issue":"2","key":"5862_CR4","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1158\/1078-0432.CCR-1146-03","volume":"10","author":"JL Mohler","year":"2004","unstructured":"Mohler JL, Gregory CW, Ford OH III, Kim D, Weaver CM, Petrusz P et al (2004) The androgen axis in recurrent prostate cancer. Clin Cancer Res 10(2):440\u2013448","journal-title":"Clin Cancer Res"},{"issue":"5","key":"5862_CR5","doi-asserted-by":"publisher","first-page":"479","DOI":"10.6004\/jnccn.2019.0023","volume":"17","author":"JL Mohler","year":"2019","unstructured":"Mohler JL, Antonarakis ES, Armstrong AJ, D\u2019Amico AV, Davis BJ, Dorff T et al (2019) Prostate cancer, version 2.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 17(5):479\u2013505","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"5862_CR6","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.euf.2022.08.007","volume":"9","author":"P Mandel","year":"2023","unstructured":"Mandel P, Hoeh B, Wenzel M, Preisser F, Tian Z, Tilki D et al (2023) Triplet or doublet therapy in metastatic Hormone-sensitive prostate cancer patients: A systematic review and network Meta-analysis. Eur Urol Focus 9(1):96\u2013105","journal-title":"Eur Urol Focus"},{"issue":"8","key":"5862_CR7","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1056\/NEJMoa1503747","volume":"373","author":"CJ Sweeney","year":"2015","unstructured":"Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M et al (2015) Chemohormonal therapy in metastatic Hormone-Sensitive prostate cancer. N Engl J Med 373(8):737\u2013746","journal-title":"N Engl J Med"},{"issue":"4","key":"5862_CR8","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1056\/NEJMoa1704174","volume":"377","author":"K Fizazi","year":"2017","unstructured":"Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY et al (2017) Abiraterone plus prednisone in metastatic, Castration-Sensitive prostate cancer. N Engl J Med 377(4):352\u2013360","journal-title":"N Engl J Med"},{"issue":"5","key":"5862_CR9","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/S1470-2045(19)30082-8","volume":"20","author":"K Fizazi","year":"2019","unstructured":"Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY et al (2019) Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet Oncol 20(5):686\u2013700","journal-title":"Lancet Oncol"},{"key":"5862_CR10","doi-asserted-by":"publisher","unstructured":"Yamada Y, Naruse K, Nakamura K, Taki T, Tobiume M, Zennami K et al (2010) Investigation of risk factors for prostate cancer patients with bone metastasis based on clinical data. Exp Ther Med [Internet].;1(4):635\u20139. Available from: https:\/\/www.spandidos-publications.com\/https:\/\/doi.org\/10.3892\/etm_00000099","DOI":"10.3892\/etm_00000099"},{"key":"5862_CR11","doi-asserted-by":"crossref","unstructured":"Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG (2009) Research electronic data capture (REDCap)\u2014A metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform [Internet].;42(2):377\u201381. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S1532046408001226","DOI":"10.1016\/j.jbi.2008.08.010"},{"key":"5862_CR12","doi-asserted-by":"crossref","unstructured":"Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O\u2019Neal L et al (2019) The REDCap consortium: Building an international community of software platform partners. J Biomed Inform [Internet].;95:103208. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S1532046419301261","DOI":"10.1016\/j.jbi.2019.103208"},{"key":"5862_CR13","doi-asserted-by":"crossref","unstructured":"Epstein JI, Egevad L, Amin MB, Delahunt B, Srigley JR, Humphrey PA et al (2016) The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System. Am J Surg Pathol [Internet].;40(2):244\u201352. Available from: https:\/\/journals.lww.com\/ajsp\/Fulltext\/2016\/02000\/The_2014_International_Society_of_Urological.10.aspx","DOI":"10.1097\/PAS.0000000000000530"},{"issue":"1","key":"5862_CR14","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1159\/000475018","volume":"28","author":"T J\u00f8rgensen","year":"1995","unstructured":"J\u00f8rgensen T, M\u00fcller C, Kaalhus O, Danielsen HE, Tveter KJ (1995) Extent of disease based on initial bone scan: important prognostic predictor for patients with metastatic prostatic cancer. Experience from the Scandinavian prostatic cancer group study 2 (SPCG-2). Eur Urol 28(1):40\u201346","journal-title":"Eur Urol"},{"key":"5862_CR15","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.clinimag.2020.12.016","volume":"78","author":"A Yoshida","year":"2021","unstructured":"Yoshida A, Higashiyama S, Kawabe J (2021) Assessment of a software for semi-automatically calculating the bone scan index on bone scintigraphy scans. Clin Imaging 78:14\u201318","journal-title":"Clin Imaging"},{"issue":"3","key":"5862_CR16","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.euo.2018.10.011","volume":"2","author":"S Akamatsu","year":"2019","unstructured":"Akamatsu S, Kubota M, Uozumi R, Narita S, Takahashi M, Mitsuzuka K et al (2019) Development and validation of a novel prognostic model for predicting overall survival in Treatment-na\u00efve Castration-sensitive metastatic prostate cancer. Eur Urol Oncol 2(3):320\u2013328","journal-title":"Eur Urol Oncol"},{"key":"5862_CR17","doi-asserted-by":"publisher","unstructured":"Nuhn P, Vaghasia AM, Goyal J, Zhou XC, Carducci MA, Eisenberger MA et al (2014) Association of pretreatment neutrophil-to-lymphocyte ratio (NLR) and overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with first-line docetaxel. BJU Int [Internet].;114(6b):E11\u20137. Available from: https:\/\/doi.org\/10.1111\/bju.12531","DOI":"10.1111\/bju.12531"},{"key":"5862_CR18","doi-asserted-by":"crossref","unstructured":"Yin X, Xiao Y, Li F, Qi S, Yin Z, Gao J (2016) Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Prostate Cancer: A Systematic Review and Meta-analysis. Medicine [Internet].;95(3):e2544\u2013e2544. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/26817900","DOI":"10.1097\/MD.0000000000002544"},{"issue":"16","key":"5862_CR19","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1002\/pros.24619","volume":"83","author":"Y Yamada","year":"2023","unstructured":"Yamada Y, Sakamoto S, Sato K, Saito S, Kanesaka M, Rii J et al (2023) Clinical utility of the prognostic nutritional index in patients with metastatic hormone-sensitive prostate cancer: A retrospective, multicenter, cohort study. Prostate 83(16):1610\u20131618","journal-title":"Prostate"},{"issue":"1","key":"5862_CR20","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1186\/s13104-021-05641-5","volume":"14","author":"S Nakanishi","year":"2021","unstructured":"Nakanishi S, Goya M, Tamaki M, Oshiro T, Saito S (2021) Three-month early change in prostate-specific antigen levels as a predictive marker for overall survival during hormonal therapy for metastatic hormone-sensitive prostate cancer. BMC Res Notes 14(1):227","journal-title":"BMC Res Notes"},{"key":"5862_CR21","doi-asserted-by":"publisher","unstructured":"Nuzzo PV, Pederzoli F, Saieva C, Zanardi E, Fotia G, Malgeri A et al (2023) Clinical impact of volume of disease and time of metastatic disease presentation on patients receiving enzalutamide or abiraterone acetate plus prednisone as first-line therapy for metastatic castration-resistant prostate cancer. J Transl Med [Internet].;21(1):75. Available from: https:\/\/doi.org\/10.1186\/s12967-022-03861-2","DOI":"10.1186\/s12967-022-03861-2"},{"key":"5862_CR22","doi-asserted-by":"publisher","unstructured":"Wenzel M, Hoeh B, Humke C, Koll F, Cano Garcia C, Siech C et al (2024) Influence of metastatic sites and burden on oncological outcomes in patients progressing to metastatic castration resistant prostate cancer. World J Urol [Internet].;42(1):615. Available from: https:\/\/link.springer.com\/https:\/\/doi.org\/10.1007\/s00345-024-05341-2","DOI":"10.1007\/s00345-024-05341-2"},{"issue":"10162","key":"5862_CR23","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.1016\/S0140-6736(18)32486-3","volume":"392","author":"CC Parker","year":"2018","unstructured":"Parker CC, James ND, Brawley CD, Clarke NW, Hoyle AP, Ali A et al (2018) Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet 392(10162):2353\u20132366","journal-title":"Lancet"},{"issue":"20","key":"5862_CR24","doi-asserted-by":"publisher","first-page":"3595","DOI":"10.1200\/JCO.23.00041","volume":"41","author":"M Hussain","year":"2023","unstructured":"Hussain M, Tombal B, Saad F, Fizazi K, Sternberg CN, Crawford ED et al (2023) Darolutamide plus Androgen-Deprivation therapy and docetaxel in metastatic Hormone-Sensitive prostate cancer by disease volume and risk subgroups in the phase III ARASENS trial. J Clin Oncol 41(20):3595\u20133607","journal-title":"J Clin Oncol"},{"issue":"4","key":"5862_CR25","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1111\/cas.14722","volume":"112","author":"M Shiota","year":"2021","unstructured":"Shiota M, Terada N, Saito T, Yokomizo A, Kohei N, Goto T et al (2021) Differential prognostic factors in low- and high-burden de Novo metastatic hormone-sensitive prostate cancer patients. Cancer Sci 112(4):1524\u20131533","journal-title":"Cancer Sci"},{"key":"5862_CR26","doi-asserted-by":"crossref","unstructured":"van Leenders GJLH, Grignon DJ, Evans AJ, Kristiansen G, Kweldam CF et al (2020) The 2019 International Society of Urological Pathology (ISUP) Consensus Conference on Grading of Prostatic Carcinoma. Am J Surg Pathol [Internet].;44(8). Available from: https:\/\/journals.lww.com\/ajsp\/fulltext\/2020\/08000\/the_2019_international_society_of_urological.1.aspx","DOI":"10.1097\/PAS.0000000000001497"},{"issue":"1","key":"5862_CR27","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.pathol.2020.09.016","volume":"53","author":"C Atallah","year":"2021","unstructured":"Atallah C, van der Toi A (2021) Gleason grade 5 prostate cancer: sub-patterns and prognosis. Pathology 53(1):3\u201311","journal-title":"Pathology"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-025-05862-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-025-05862-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-025-05862-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T22:03:12Z","timestamp":1767996192000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00345-025-05862-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,11]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["5862"],"URL":"https:\/\/doi.org\/10.1007\/s00345-025-05862-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5433569\/v1","asserted-by":"object"}]},"ISSN":["1433-8726"],"issn-type":[{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,11]]},"assertion":[{"value":"11 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study received approval from the ethics committee of Hiroshima University (authorization number: E2021-2519) and was conducted in accordance with the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Consent was obtained by using an opt-out approach or written from all patients for the publication of this report.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"483"}}